These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19564153)

  • 21. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Fennell DA; Chacko A; Mutti L
    Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
    Birle DC; Hedley DW
    Cancer Res; 2007 Feb; 67(4):1735-43. PubMed ID: 17308115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
    Naujokat C; Berges C; Höh A; Wieczorek H; Fuchs D; Ovens J; Miltz M; Sadeghi M; Opelz G; Daniel V
    Immunology; 2007 Jan; 120(1):120-32. PubMed ID: 17083604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The proteasome: structure, function, and role in the cell.
    Adams J
    Cancer Treat Rev; 2003 May; 29 Suppl 1():3-9. PubMed ID: 12738238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
    Xu H; Ju D; Jarois T; Xie Y
    Breast Cancer Res Treat; 2008 Jan; 107(2):267-74. PubMed ID: 17431761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
    Park JW; Kim KM; Oh KJ; Rhyu IJ; Jang HS
    J Trauma; 2009 Mar; 66(3):743-8. PubMed ID: 19276748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
    Nakamura T; Tanaka K; Matsunobu T; Okada T; Nakatani F; Sakimura R; Hanada M; Iwamoto Y
    Int J Oncol; 2007 Oct; 31(4):803-11. PubMed ID: 17786311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
    Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
    Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
    Lu SF; Lu H; Shen WY; Zhang JF; Liu P; Wang YR; Wang LX; Yang H; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1006-9. PubMed ID: 18928584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.
    Sinn DI; Lee ST; Chu K; Jung KH; Kim EH; Kim JM; Park DK; Song EC; Kim BS; Yoon SS; Kim M; Roh JK
    Neurosci Res; 2007 May; 58(1):12-8. PubMed ID: 17328981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection.
    Dreger H; Westphal K; Weller A; Baumann G; Stangl V; Meiners S; Stangl K
    Cardiovasc Res; 2009 Jul; 83(2):354-61. PubMed ID: 19351736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
    Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
    Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
    Dasgupta S; Castro LM; Dulman R; Yang C; Schmidt M; Ferro ES; Fricker LD
    PLoS One; 2014; 9(7):e103604. PubMed ID: 25079948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.